Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma

Young Wha Koh, Yoon Kyung Jeon, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh

Research output: Contribution to journalArticleResearchpeer-review

26 Citations (Scopus)

Abstract

Programmed cell death protein-1 (PD-1) inhibitor may be therapeutic in patients with relapsed or refractory classical Hodgkin’s lymphoma (cHL). This study examined the prognostic significance of PD-1 and two PD-1 ligands (PD-L1 and PD-L2) in uniformly treated cHL. Diagnostic tissues from 109 cHL patients treated with a doxorubicin, bleomycin, vinblastine, and dacarbazine regimen were evaluated retrospectively by immunohistochemical analysis of PD-L1, PD-L2, and PD-1 expressions. The median follow-up time was 4.91 years (range, 0.17–17.33 years). Thirteen patients (11 %) expressed PD-1 protein in the peritumoral microenvironment, which was associated with poor overall survival (OS) (P = 0.017). PD-L1 or PD-L2 expression was not associated with OS. There was no correlation between PD-L1 and PD-1 expression or between PD-L2 and PD-1 expression. Multivariate analysis identified PD-1 protein as an independent prognostic factor for OS (P = 0.019). Subgroup analysis according to the Ann Arbor stage of cHL showed that PD-1 protein expression had a prognostic value in limited-stage cHL (P = 0.048). PD-1 is an independent prognostic factor in cHL and may allow the identification of a subgroup of patients with limited-stage cHL who require more intensive therapy and who may benefit from anti-PD-1 agents.

Original languageEnglish
Pages (from-to)7507-7514
Number of pages8
JournalTumor Biology
Volume37
Issue number6
DOIs
StatePublished - 1 Jun 2016

Fingerprint

Hodgkin Disease
Survival
Programmed Cell Death 1 Receptor
Dacarbazine
Proteins
Vinblastine
Bleomycin
Doxorubicin
Multivariate Analysis
Ligands
Therapeutics

Keywords

  • Hodgkin’s lymphoma
  • PD-1
  • PD-L1
  • PD-L2
  • Prognosis

Cite this

Koh, Young Wha ; Jeon, Yoon Kyung ; Yoon, Dok Hyun ; Suh, Cheolwon ; Huh, Jooryung. / Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. In: Tumor Biology. 2016 ; Vol. 37, No. 6. pp. 7507-7514.
@article{9917846ccd2f45898d8f8139913c1a9d,
title = "Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma",
abstract = "Programmed cell death protein-1 (PD-1) inhibitor may be therapeutic in patients with relapsed or refractory classical Hodgkin’s lymphoma (cHL). This study examined the prognostic significance of PD-1 and two PD-1 ligands (PD-L1 and PD-L2) in uniformly treated cHL. Diagnostic tissues from 109 cHL patients treated with a doxorubicin, bleomycin, vinblastine, and dacarbazine regimen were evaluated retrospectively by immunohistochemical analysis of PD-L1, PD-L2, and PD-1 expressions. The median follow-up time was 4.91 years (range, 0.17–17.33 years). Thirteen patients (11 {\%}) expressed PD-1 protein in the peritumoral microenvironment, which was associated with poor overall survival (OS) (P = 0.017). PD-L1 or PD-L2 expression was not associated with OS. There was no correlation between PD-L1 and PD-1 expression or between PD-L2 and PD-1 expression. Multivariate analysis identified PD-1 protein as an independent prognostic factor for OS (P = 0.019). Subgroup analysis according to the Ann Arbor stage of cHL showed that PD-1 protein expression had a prognostic value in limited-stage cHL (P = 0.048). PD-1 is an independent prognostic factor in cHL and may allow the identification of a subgroup of patients with limited-stage cHL who require more intensive therapy and who may benefit from anti-PD-1 agents.",
keywords = "Hodgkin’s lymphoma, PD-1, PD-L1, PD-L2, Prognosis",
author = "Koh, {Young Wha} and Jeon, {Yoon Kyung} and Yoon, {Dok Hyun} and Cheolwon Suh and Jooryung Huh",
year = "2016",
month = "6",
day = "1",
doi = "10.1007/s13277-015-4622-5",
language = "English",
volume = "37",
pages = "7507--7514",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "SAGE Publications Inc.",
number = "6",

}

Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. / Koh, Young Wha; Jeon, Yoon Kyung; Yoon, Dok Hyun; Suh, Cheolwon; Huh, Jooryung.

In: Tumor Biology, Vol. 37, No. 6, 01.06.2016, p. 7507-7514.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma

AU - Koh, Young Wha

AU - Jeon, Yoon Kyung

AU - Yoon, Dok Hyun

AU - Suh, Cheolwon

AU - Huh, Jooryung

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Programmed cell death protein-1 (PD-1) inhibitor may be therapeutic in patients with relapsed or refractory classical Hodgkin’s lymphoma (cHL). This study examined the prognostic significance of PD-1 and two PD-1 ligands (PD-L1 and PD-L2) in uniformly treated cHL. Diagnostic tissues from 109 cHL patients treated with a doxorubicin, bleomycin, vinblastine, and dacarbazine regimen were evaluated retrospectively by immunohistochemical analysis of PD-L1, PD-L2, and PD-1 expressions. The median follow-up time was 4.91 years (range, 0.17–17.33 years). Thirteen patients (11 %) expressed PD-1 protein in the peritumoral microenvironment, which was associated with poor overall survival (OS) (P = 0.017). PD-L1 or PD-L2 expression was not associated with OS. There was no correlation between PD-L1 and PD-1 expression or between PD-L2 and PD-1 expression. Multivariate analysis identified PD-1 protein as an independent prognostic factor for OS (P = 0.019). Subgroup analysis according to the Ann Arbor stage of cHL showed that PD-1 protein expression had a prognostic value in limited-stage cHL (P = 0.048). PD-1 is an independent prognostic factor in cHL and may allow the identification of a subgroup of patients with limited-stage cHL who require more intensive therapy and who may benefit from anti-PD-1 agents.

AB - Programmed cell death protein-1 (PD-1) inhibitor may be therapeutic in patients with relapsed or refractory classical Hodgkin’s lymphoma (cHL). This study examined the prognostic significance of PD-1 and two PD-1 ligands (PD-L1 and PD-L2) in uniformly treated cHL. Diagnostic tissues from 109 cHL patients treated with a doxorubicin, bleomycin, vinblastine, and dacarbazine regimen were evaluated retrospectively by immunohistochemical analysis of PD-L1, PD-L2, and PD-1 expressions. The median follow-up time was 4.91 years (range, 0.17–17.33 years). Thirteen patients (11 %) expressed PD-1 protein in the peritumoral microenvironment, which was associated with poor overall survival (OS) (P = 0.017). PD-L1 or PD-L2 expression was not associated with OS. There was no correlation between PD-L1 and PD-1 expression or between PD-L2 and PD-1 expression. Multivariate analysis identified PD-1 protein as an independent prognostic factor for OS (P = 0.019). Subgroup analysis according to the Ann Arbor stage of cHL showed that PD-1 protein expression had a prognostic value in limited-stage cHL (P = 0.048). PD-1 is an independent prognostic factor in cHL and may allow the identification of a subgroup of patients with limited-stage cHL who require more intensive therapy and who may benefit from anti-PD-1 agents.

KW - Hodgkin’s lymphoma

KW - PD-1

KW - PD-L1

KW - PD-L2

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84949988925&partnerID=8YFLogxK

U2 - 10.1007/s13277-015-4622-5

DO - 10.1007/s13277-015-4622-5

M3 - Article

VL - 37

SP - 7507

EP - 7514

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 6

ER -